Bionity.com reports in the news about MucosaTec winning the Innovation Award 2024. MucosaTec’s technology comprises novel bifunctional peptides that provide a flexible and cost-effective method of combating viral infections. The peptides bind to both the pathogen and the mucus, our body’s natural barrier, and thus immobilize pathogens. This innovation could form the basis for the development of antiviral drugs in the future. The recent Covid-19 pandemic, for example, as well as outbreaks of SARS-CoV, MERS-CoV, Ebola and influenza, have highlighted the importance of developing antiviral drugs to combat future epidemics and pandemics.
Bionity.com is the leading portal for life sciences and pharmaceuticals in the key markets of Europe, the USA and Asia. More than 2.4 million users from industry, research and science inform themselves here about current events in these dynamic markets. Regardless of whether it is about the latest trends and technologies in the laboratory or in production.
